Hematologic Oncology

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.

Justin Kaner, MD, discusses the latest advances surrounding menin inhibitors in acute myeloid leukemia.

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

A committee recommended a phase 1/2 study of ribaxamase for the prevention of acute graft-vs-host-disease proceed with enrollment for a third cohort.

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

ICT01 plus azacitidine and venetoclax has received fast track designation from the FDA in patients with untreated AML unfit for induction chemotherapy.

Shyam A. Patel, MD, PhD, discusses the impact of donor-engrafted clonal hematopoiesis on the risk of disease relapse and survival outcomes with allo- and auto-HSCT.

Amitkumar Mehta, MD, discusses FDA-approved treatment options for patients with diffuse large B-cell lymphoma and follicular lymphoma in later lines.

Pacritinib led to improved hematologic outcomes and overall survival in real-world patients with myelofibrosis.

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.